Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 11/20 | 0.37 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.35 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.35 |
| ▸ | OGA | O60502 | 7/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3932906 | 1.00 | AOC3 (0.37) | AOC3S1PR4S1PR1S1PR3S1PR5 | |
| SCHEMBL3940980 | 1.00 | AOC3 (0.37) | AOC3S1PR4S1PR1S1PR3S1PR5 | |
| SCHEMBL3941993 | 1.00 | AOC3 (0.37) | AOC3S1PR4S1PR1S1PR3S1PR5 | |
| SCHEMBL4867043 | 0.96 | OGA (0.40) | AOC3S1PR5OGA | |
| SCHEMBL4984840 | 0.96 | OGA (0.40) | AOC3S1PR5OGA | |
| SCHEMBL4867048 | 0.96 | OGA (0.40) | AOC3S1PR5OGA | |
| SCHEMBL4984823 | 0.96 | OGA (0.40) | AOC3S1PR5OGA | |
| SCHEMBL4876151 | 0.96 | AOC3 (0.38) | AOC3OGA | |
| SCHEMBL4876176 | 0.96 | AOC3 (0.38) | AOC3OGA | |
| SCHEMBL5550218 | 0.94 | AOC3 (0.38) | AOC3OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1786792-B1 | THIAZOLE DERIVATIVES HAVING VAP-1 INHIBITORY ACTIVITY | ASTELLAS PHARMA INC (JP) | 2009-04-08 | — | — | EP | disclosed |
| US-20070254931-A1 | Thiazole Derivatives Having Vap-1 Inhibitory Activity | ASTELLAS PHARMA INC. (JP) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254931-A1 | Thiazole Derivatives Having Vap-1 Inhibitory Activity | VCAM1, VAPB, VAPA | AOC3 386/4885S1PR4 2482/4885S1PR1 1666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.